Trial Profile
Phase I Trial of Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 23 Apr 2020
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Adverse reactions
- 20 Apr 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 10 Apr 2019 Planned number of patients changed from 18 to 12.
- 14 Aug 2018 New trial record